Search clinical trials for: JNJ-64232025 IV

Total 4276 results

Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Recruiting

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

Hematological Malignancies

United States, Netherlands, Spain, France, Sweden
Janssen Research & Development, LLC

Completed

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Canada, United States, Czechia, Israel, Italy, Korea, Republic of, Brazil, United Kingdom, Japan, Taiwan, Australia, Poland, Spain, France, Russian Federation, Sweden, Ukraine, Greece
Janssen Research & Development, LLC

Completed

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Lymphoma, Non-Hodgkin

Denmark, Israel, Spain, Australia
Janssen-Cilag International NV

Completed

A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants

Healthy
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Janssen Pharmaceutical K.K.

Completed

Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Healthy

Belgium
Janssen Cilag N.V./S.A.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Healthy

United States
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)

Urinary Bladder Neoplasms

United States, Korea, Republic of, France, Israel, Spain, Italy, United Kingdom, Belgium, Netherlands, Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers

Healthy
Janssen Research & Development, LLC

Completed

A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States, Israel, Korea, Republic of, Netherlands, Belgium, Spain, Australia, Poland, France, Georgia, Moldova, Republic of, Ukraine
Johnson & Johnson Enterprise Innovation Inc.

Recruiting

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Advanced Solid Tumors

United States
Janssen Cilag N.V./S.A.

Completed

Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants

Healthy

Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers

Health

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

Low Back Pain | Low Back Pain, Recurrent

United States, Belgium, Canada, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants

Healthy

United States
Janssen R&D Ireland

Completed

A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants

Healthy Participants

Belgium
Janssen Research & Development, LLC

Terminated

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Alzheimer Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

Alzheimer's Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants

Healthy

Belgium
Janssen Sciences Ireland UC

Completed

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection (REEF-1)

Hepatitis B, Chronic

Belgium, United States, Japan, Korea, Republic of, France, Hong Kong, Canada, Italy, Thailand, Germany, Malaysia, Spain, Russian Federation, Turkey, United Kingdom, Poland, Brazil, Czechia, China
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

Healthy

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Diabetic Neuropathy

United States
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Chengappa, K.N. Roy, MD
National Institutes of Health (NIH)

Completed

Test of Novel Drug for Smoking Cessation (UH3-P2)

Smoking Cessation

United States
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Healthy

Belgium
Janssen Pharmaceutical K.K.

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors

Advanced Stage Solid Tumors

Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Neoplasms

Canada, Israel, Spain
Janssen Research & Development, LLC

Completed

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

Prostatic Neoplasms

United States, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)

Multiple Myeloma

United States, Japan
Janssen Research & Development, LLC

Completed

A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors

Neoplasms

United States, Canada
Janssen Sciences Ireland UC

No longer available

Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

Respiratory Syncytial Virus
Janssen Research & Development, LLC

Completed

A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants

Healthy

United States
Aragon Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

Obesity

United States

3

Subscribe